Close Menu

KRAS Biomarkers

News and reporting on KRAS biomarkers.

The company is testing the RAF/MEK inhibitor and FAK inhibitor combination in a randomized study after promising Phase I data presented at AACR.

News items for the week of March 15, 2021. 

The company was cleared to begin a Phase I/II trial of its lead candidate, a therapeutic vaccine that can potentially treat and prevent recurrence of KRAS-mutated cancers.

The company will use the latest funding to begin Phase I/II trials for its lead candidate, ELI-002, in KRAS-mutated cancers.

The research and development partnership will focus on advancing Mirati's KRAS G12C and KRAS G12D inhibitors as treatments for solid cancers.

The company is hoping to use the funds to advance certain RAS inhibitors in its pipeline into clinical trials, as well as for general corporate expenses.

The company is assessing onvansertib with Onyvide and chemo as a second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Pages